Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

118.13 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
40 41 Next >
Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years
Via Benzinga
2 Blue Chip Dividend Stocks That Are Top Buys in August
These two dividend-paying healthcare stocks stand out as top buys right now. 
Via The Motley Fool
2 Best Healthcare Stocks to Buy Right Now
The healthcare sector has plenty of growth tailwinds. 
Via The Motley Fool
Boston Scientific's Farapulse Eyes Stronger US Market Position With Potential FDA Approval
Boston Scientific Corp (NYSE: BSX) will present results from ADVENT pivotal trial for its Farapulse Pulsed Field Ablation (PFA) system at the 2023 European Society of Cardiology Congress on 27 August.... 
Via Benzinga
Exposures Product Safety
How Is The Market Feeling About Abbott Laboratories?
Via Benzinga
Is Abbott Laboratories Stock a Buy Now?
The healthcare company recently boosted its guidance. 
Via The Motley Fool
This Is What Whales Are Betting On Abbott Laboratories
Via Benzinga
Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years
Via Benzinga
Looking Into Abbott Laboratories's Recent Short Interest
Via Benzinga
Is AbbVie Still a Good Dividend Stock to Buy?
Find out if AbbVie can overcome sinking sales of its top-selling product. 
Via The Motley Fool
2 Top Stocks to Buy in August and Hold Forever
These companies won't disappoint long-term investors. 
Via The Motley Fool
Does Abbott Laboratories' Dividend Make It a Buy?
There's a lot to like about this business when it comes to dividends. 
Via The Motley Fool
Glucose Monitor Maker DexCom In Buy Zone After Gapping Higher
Strong Q2 earnings performance propelled DexCom higher. Investors cheered the glucose monitoring leader's bullish sales view and international expansion plans. 
Via MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Looking At Abbott Laboratories's Recent Unusual Options Activity
Via Benzinga
Abbott Laboratories (ABT) Q2 2023 Earnings Call Transcript
ABT earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Dexcom Earnings Tops Estimates, Medical Device Maker Hikes Outlook
Dexcom stock rose after the company reported Q2 earnings and revenue that topped Wall Street targets and raised full-year sales guidance. 
Via Investor's Business Daily
Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform – Insights From The Discussion
Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. 
Via Benzinga
Abbott Recalls Amplatzer Steerable Delivery Sheath On Risk Of Air Embolism
Abbott Laboratories (NYSE: ABT) is recalling the Amplatzer Steerable Delivery Sheath due to an increased  
Via Benzinga
2 Top Dividend Stocks to Buy and Hold Forever
They have been paying dividends for a long time. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Russia Is Seizing European Company Assets — What US Businesses Are Still At Risk?
Via Benzinga
3 Ultrareliable Dividend Stocks to Buy and Hold for Decades
These stocks have decades of annual dividend raises under their belts, and rising healthcare costs mean there could be plenty more to come. 
Via The Motley Fool
Apple To Rally Over 17%? Here Are 10 Other Analyst Forecasts For Monday
Citigroup raised the price target for Cintas Corporation (NASDAQ: CTAS) from $540 to $550. Citigroup analyst Leo Carrington downgraded the stock from Buy to Neutral. Cintas shares fell 0.8% to $503.43... 
Via Benzinga
Abbott's Higher Than Expected Q2 Earnings: Analyst Foresees Strong Performance In 2024
Thursday, Abbott Laboratories (NYSE: ABT) reported better-than-expected Q2 earnings. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
Via Benzinga
Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review
But all the major indexes are at or near 15-month highs. 
Via Investor's Business Daily
J&J, Abbott Labs And JPM Among Jim Cramer's Top Picks As Market Shifts Focus From Tech
Via Benzinga
Johnson & Johnson's Inflection Point: What it Means for Investors
Johnson & Johnson stock and the company show signs of strength and growth while offering value and yield relative to its peer Abbott Laboratories. 
Via MarketBeat
Exposures COVID-19
Abbott Laboratories Has the Prescription for Higher Share Prices
Abbott Laboratories stock is ready to rebound after a year of correction. The decline of COVID is priced into the market, and organic growth is accelerating. 
Via MarketBeat
Exposures COVID-19
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
40 41 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.